Logo

CHRS

Coherus Oncology, Inc.

CHRS

Coherus Oncology, Inc. • NASDAQ
$1.35 ▲ 3.44% (+0.04)
Market Cap $157.06 M
52w High $2.43
52w Low $0.71
Dividend Yield 0%
P/E 2.46
Volume 745.48K
Outstanding Shares 115.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $11.571M ▲ $52.183M ▼ $-35.531M ▼ -307.069% ▼ $-0.31 ▲ $-41.226M ▲
Q2-2025 $10.254M ▲ $52.345M ▲ $297.767M ▲ 2.904K% ▲ $-0.36 ▲ $-41.569M ▲
Q1-2025 $7.599M ▼ $50.381M ▼ $-56.569M ▼ -744.427% ▼ $-0.49 ▼ $-44.202M ▲
Q4-2024 $54.144M ▼ $62.532M ▲ $-50.696M ▼ -93.632% ▼ $-0.44 ▼ $-44.317M ▼
Q3-2024 $70.774M $56.42M $-10.751M -15.191% $-0.093 $-3.84M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $191.663M ▼ $516.519M ▲ $428.745M ▲ $87.774M ▼
Q2-2025 $237.637M ▲ $439.464M ▲ $319.637M ▼ $119.827M ▲
Q1-2025 $82.411M ▼ $371.066M ▼ $554.536M ▼ $-183.47M ▼
Q4-2024 $125.987M ▲ $448.533M ▼ $580.523M ▼ $-131.99M ▼
Q3-2024 $97.69M $505M $592.973M $-87.973M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-35.531M ▼ $-46.339M ▲ $-67.227M ▼ $2K ▲ $-113.564M ▼ $-46.339M ▲
Q2-2025 $297.767M ▲ $-46.632M ▼ $462.638M ▲ $-281.524M ▼ $134.482M ▲ $-46.632M ▼
Q1-2025 $-56.569M ▼ $-25.826M ▼ $-17.486M ▼ $-264K ▼ $-43.576M ▼ $-25.826M ▼
Q4-2024 $-50.696M ▼ $28.608M ▲ $-542K ▼ $231K ▲ $28.297M ▲ $28.608M ▲
Q3-2024 $-10.751M $-62.016M $444K $-167K $-61.739M $-62.016M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product and Service Other
Product and Service Other
 $10.00M ▲$0 ▼$0 ▲$0 ▲
Product
Product
 $190.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has shrunk meaningfully from earlier years but has stabilized and ticked up slightly more recently. Profitability metrics have improved: gross profit remains positive, operating losses have narrowed, and earnings before interest and depreciation have moved into modestly positive territory. The company has just swung back to a small net profit after several years of losses. That said, the core operating business is still fragile, and recent profitability likely reflects one‑time effects and the business transition as much as durable earnings power.

Balance Sheet

Balance Sheet The balance sheet shows a company that has been drawing down its resources over time. Total assets and cash are lower than a few years ago, while debt remains significant. Shareholder equity has turned negative and, although it improved slightly in the most recent year, it still signals a leveraged and financially stretched position. The divestiture and rebranding have likely helped extend the cash runway, but the company does not have a particularly strong cushion and remains sensitive to setbacks or delays in its pipeline.

Cash Flow

Cash Flow Cash generation has been a challenge. Operating cash flow was solidly positive several years ago but turned negative and stayed that way, though the most recent year shows the burn shrinking to near break‑even. Free cash flow mirrors this pattern since capital spending is minimal. In practical terms, the company is close to cash‑neutral on operations but not yet consistently self‑funding, so its ability to sustain R&D and commercialization depends on maintaining tight cost control, using its existing cash, and potentially accessing external capital over time.

Competitive Edge

Competitive Edge Coherus has deliberately repositioned itself from a biosimilar player to a focused oncology company. Its key marketed drug, LOQTORZI, holds a unique position as the only preferred treatment for a specific head-and-neck cancer in U.S. guidelines, giving it a defensible niche and a foothold in immuno‑oncology. The new strategy emphasizes differentiated mechanisms and proprietary combinations, which can create a competitive moat if clinical results are strong. However, it operates in a very crowded field against much larger pharmaceutical companies, relies heavily on a single approved product, and must execute well on partnerships and label expansions to strengthen its market position.

Innovation and R&D

Innovation and R&D R&D is clearly the core of the story. The company is targeting sophisticated immune pathways in the tumor microenvironment, with first‑in‑class antibodies against IL‑27 and CCR8 and a next‑generation PD‑1 backbone. This approach, if successful, could unlock new combination regimens and more durable responses, and the early data are described as encouraging. A strong scientific advisory board and a focused pipeline support this innovative stance. At the same time, most assets are still in early or mid‑stage trials, so scientific, clinical, and regulatory risks remain high, and timelines for value realization run over several years.

Summary

Coherus Oncology is a small, transitioning biotech moving from a legacy biosimilar base to a concentrated bet on innovative cancer immunotherapy. Financially, it has shifted from deep losses toward break‑even, even posting a small profit, but its balance sheet is thin, with negative equity and limited cash relative to its ambitions. Operationally, it now depends on a single commercial product plus a high‑risk, high‑potential pipeline. The company’s future will largely be driven by clinical trial outcomes, LOQTORZI’s adoption and label expansion, and its ability to manage finances carefully while advancing multiple oncology programs in a highly competitive landscape.

NEWS

November 7, 2025 · 9:00 AM UTC

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Read more

November 6, 2025 · 4:14 PM UTC

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 6, 2025 · 1:54 PM UTC

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Read more

October 30, 2025 · 8:30 AM UTC

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Read more

October 23, 2025 · 8:30 AM UTC

Coherus Oncology to Participate in Upcoming Investor Conferences

Read more